6VBO

Crystal structure of anti-HIV-1 antibody DH813 bound to gp120 V2 peptide


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.68 Å
  • R-Value Free: 0.208 
  • R-Value Work: 0.175 
  • R-Value Observed: 0.176 

wwPDB Validation 3D Report Full Report



Literature

HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions.

Easterhoff, D.Pollara, J.Luo, K.Janus, B.Gohain, N.Williams, L.D.Tay, M.Z.Monroe, A.Peachman, K.Choe, M.Min, S.Lusso, P.Zhang, P.Go, E.P.Desaire, H.Bonsignori, M.Hwang, K.K.Beck, C.Kakalis, M.O'Connell, R.J.Vasan, S.Kim, J.H.Michael, N.L.Excler, J.L.Robb, M.L.Rerks-Ngarm, S.Kaewkungwal, J.Pitisuttithum, P.Nitayaphan, S.Sinangil, F.Tartaglia, J.Phogat, S.Wiehe, K.Saunders, K.O.Montefiori, D.C.Tomaras, G.D.Moody, M.A.Arthos, J.Rao, M.Joyce, M.G.Ofek, G.A.Ferrari, G.Haynes, B.F.

(2020) JCI Insight 5

  • DOI: 10.1172/jci.insight.131437
  • Structures With Same Primary Citation

  • PubMed Abstract: 
  • In the RV144 HIV-1 phase III trial, vaccine efficacy directly correlated with the magnitude of the variable region 2-specific (V2-specific) IgG antibody response, and in the presence of low plasma IgA levels, with the magnitude of plasma antibody-dep ...

    In the RV144 HIV-1 phase III trial, vaccine efficacy directly correlated with the magnitude of the variable region 2-specific (V2-specific) IgG antibody response, and in the presence of low plasma IgA levels, with the magnitude of plasma antibody-dependent cellular cytotoxicity. Reenrollment of RV144 vaccinees in the RV305 trial offered the opportunity to define the function, maturation, and persistence of vaccine-induced V2-specific and other mAb responses after boosting. We show that the RV144 vaccine regimen induced persistent V2 and other HIV-1 envelope-specific memory B cell clonal lineages that could be identified throughout the approximately 11-year vaccination period. Subsequent boosts increased somatic hypermutation, a critical requirement for antibody affinity maturation. Characterization of 22 vaccine-induced V2-specific mAbs with epitope specificities distinct from previously characterized RV144 V2-specific mAbs CH58 and CH59 found increased in vitro antibody-mediated effector functions. Thus, when inducing non-neutralizing antibodies, one method by which to improve HIV-1 vaccine efficacy may be through late boosting to diversify the V2-specific response to increase the breadth of antibody-mediated anti-HIV-1 effector functions.


    Organizational Affiliation

    Department of Medicine and.



Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
DH813 light chainL218Homo sapiensMutation(s): 0 
Protein Feature View
 ( Mouse scroll to zoom / Hold left click to move )
  • Reference Sequence

Find similar proteins by: Sequence  |  Structure

Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
DH813 heavy chainH221Homo sapiensMutation(s): 0 
Protein Feature View
 ( Mouse scroll to zoom / Hold left click to move )
  • Reference Sequence

Find similar proteins by: Sequence  |  Structure

Entity ID: 3
MoleculeChainsSequence LengthOrganismDetails
Envelope glycoprotein gp160C22Human immunodeficiency virus 1Mutation(s): 0 
Gene Names: env
Find proteins for I2E6B7 (Human immunodeficiency virus 1)
Explore I2E6B7 
Go to UniProtKB:  I2E6B7
Protein Feature View
 ( Mouse scroll to zoom / Hold left click to move )
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.68 Å
  • R-Value Free: 0.208 
  • R-Value Work: 0.175 
  • R-Value Observed: 0.176 
  • Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 55.57α = 90
b = 63.92β = 92.96
c = 70.58γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
PDB_EXTRACTdata extraction
HKL-2000data reduction
HKL-2000data scaling
PHENIXphasing

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

  • Deposited Date: 2019-12-19 
  • Released Date: 2020-02-12 
  • Deposition Author(s): Janus, B.M., Ofek, G.

Revision History 

  • Version 1.0: 2020-02-12
    Type: Initial release